Overexpression of HER2 is often related to a poor clinical prognosis [21], but a combination therapy of trastuzumab and lapatinib (tyrosine kinase inhibitor) was reported to have good efficacy on HER2-positive breast cancer [22]. Here, ERBB2 is linked to breast carcinoma.